The NYSCF Global Stem Cell Array is a revolutionary robotic technology, developed by NYSCF, that automates and standardizes the production of stem cell lines and adult cell types.
NYSCF has embarked on a program to create an array of stem cell lines that will represent the majority of human genetics—stem cell “avatars” for the world’s population—a development that holds the potential to reshape both personal healthcare and also the medical industry.
The NYSCF ArrayTM technology enables scientists for the first time to functionalize human genetics by merging data from the human genome with our own biology – accelerating new therapies and cures for patients using actual human cells affected by disease.
This pioneering automation technology allows NYSCF to:
- Standardize and scale up production of identical induced pluripotent stem (iPS) cells, which are stem cells made from an individual’s own skin or blood cells.
- Study iPS cells from thousands of patients, reflecting the genetic diversity of the global population and enabling scientists to detect patterns that are only discernable when examining a large population of patients, and which show how different genetic mutations impact individual disease symptoms.
- Conduct clinical trials in a petri dish using the actual affected human cell types – from patients rather than from surrogate models (e.g. animals). Testing drugs and therapies directly on human cells allows for a much more accurate recapitulation of human disease than the animal models that are traditionally used for drug development.
- Develop more effective, safer, and less expensive new drugs to target the causes of disease, by factoring in genetic differences during the development process. This revolutionary approach will help “de-risk” projects that pharmaceutical companies would typically avoid.
Future of Personalized Medicine
Currently, bringing a drug to market takes on average:
- 13 years
- $4 billion
- 99% failure rate
The NYSCF Array will cut down years of time and billions of dollars currently spent on drug development and clinical trials to ultimately accelerate the approval of new drugs and therapies by regulatory agencies.
Learn more from the NYSCF CEO and Co-founder Susan L Solomon in her Ted Talk.
In 2015, NYSCF scientists published a paper describing the NYSCF Array in the journal Nature Methods. Read the publication and learn more about the NYSCF Array’s capabilities and the validation of NYSCF-generated stem cells lines in the press release.
Partnerships Enabled by The NYSCF Array
- Studying psychiatric disorders from an individuals own skin or blood with the Broad Institute of MIT and Harvard
- Investigating undiagnosed diseases with the National Institutes of Health Undiagnosed Disease Program
- Creating stem cells from babies and infants with Cord Blood Registry Systems Inc.
- Automating stem cell production from blood samples with Q-State Biosciences
- Helping Charcot-Marie-Tooth Association understand neuropathy disorders to design personalized treatments
- Giving Beyond Batten Disease Foundation the power to research what happens to cells affected by juvenile Batten disease
- Generating iPS cells for Personalgenomes.org
Access to the stem cell lines produced by The NYSCF Array are available through the NYSCF Repository in a collaboration with eagle-i, a project of Harvard Catalyst at Harvard Medical School.